13.75

8.33% -1.25

After Hours: 14.01 0.26 +1.89%

Tonix Pharmaceuticals Holding Corp (TNXP)

Overview News Price History Financials Why TNXP Down? Discussions Forecast Stock Split

Tonix Pharmaceuticals Holding Corp stock is traded at $13.75, with a volume of 408.36K. It is down -8.33% in the last 24 hours and down -4.71% over the past month. Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Previous Close:

$15.00

Open:

$14.4

24h Volume:

408.36K

Relative Volume:

0.97

Market Cap:

$184.32M

Revenue:

$13.11M

Net Income/Loss:

$-124.02M

P/E Ratio:

-0.9642

EPS:

-14.261

Net Cash Flow:

$-107.25M

1W Performance:

-12.81%

1M Performance:

-4.71%

6M Performance:

-43.21%

1Y Performance:

-52.19%

1-Day Range:

$13.75

$14.98

1-Week Range:

$13.75

$17.00

52-Week Range:

$13.07

$69.97

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile

Name

Tonix Pharmaceuticals Holding Corp

Sector

Healthcare (1113)

Industry

Biotechnology (623)

Phone

212-980-9155

Address

200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY

Employee

142

Twitter

@TONIXPharma

Next Earnings Date

2026-03-17

Latest SEC Filings

TNXP's Discussions on Twitter

Compare TNXP vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNXP Tonix Pharmaceuticals Holding Corp	13.75	201.08M	13.11M	-124.02M	-107.25M	-14.26
VRTX Vertex Pharmaceuticals Inc	453.74	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	756.73	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.16	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	692.83	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	147.60	31.97B	606.42M	-1.28B	-997.58M	-6.403

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-18-22	Initiated	Noble Capital Markets	Outperform
Apr-18-19	Upgrade	ROTH Capital	Neutral → Buy
Aug-18-17	Upgrade	ROTH Capital	Neutral → Buy
Sep-07-16	Downgrade	ROTH Capital	Buy → Neutral
Feb-17-16	Reiterated	Oppenheimer	Outperform
Nov-04-15	Initiated	Cantor Fitzgerald	Buy
Jun-12-15	Initiated	Oppenheimer	Outperform
Feb-17-15	Reiterated	ROTH Capital	Buy
Sep-29-14	Reiterated	ROTH Capital	Buy

View All

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News

08:23 AM

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain - Bitget

08:23 AM

08:10 AM

Tonix Pharmaceuticals (TNXP) Advances with Phase 1 Study on TNX-1900 - GuruFocus

08:10 AM

08:09 AM

Tonix doses first patient in migraine treatment study By Investing.com - Investing.com India

08:09 AM

07:35 AM

Tonix Pharma Begins Phase 1 Study of TNX-1900 - TipRanks

07:35 AM

07:00 AM

Tonix (NASDAQ: TNXP) doses first subject in TNX-1900 migraine study - Stock Titan

07:00 AM

06:12 AM

Q1 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat

06:12 AM

01:21 AM

FY2028 Earnings Estimate for TNXP Issued By Zacks Research - Defense World

01:21 AM

Mar 25, 2026

Tonix Pharmaceuticals Holding Corp at TD Cowen Healthcare Conference Transcript - GuruFocus

Mar 25, 2026